Furthermore, there were no cases of grade 3 and 4 capillary leak syndrome, hypersensitivity reactions, bronchospasm, or allergic reactions with single-agent dinutuximab beta, while in studies where it was co-administered with IL-2, the incidences were 13–15%, 2–21%, 8%, and 15%, respectively [9, 10]. This evidence concerns the gene IL2 and capillary leak syndrome.